GKT136901 (Standard)
GKT136901 (Standard) is the analytical standard of GKT136901. This product is intended for research and analytical applications. GKT136901 is a potent, selective and orally active inhibitor of NADPH oxidase (NOX1/4), with Kis of 160 and 165 nM, respectively. GKT136901 is also a selective and direct scavenger of peroxynitrite. GKT136901 can be used for the research of diabetic nephropathy, stroke, and neurodegeneration. GKT136901 also has anti-inflammatory activity.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98%
- No. CAS: 955272-06-7
- Fòrmula: C19H15ClN4O2
- Peso molecular:366.80
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureza y Documentación
-
Help & FAQs
-
HY-101499
GKT136901NOX1/4 Inhibitor -
HY-12298
SetanaxibNOX1/4 Inhibitor -
HY-12804
VAS2870Nox Inhibitor -
HY-100111
GLX351322NADPH Oxidase 4 Inhibitor -
HY-125944
MitoTEMPO hydrateAntioxidant -
HY-18950
GSK2795039NOX2 Inhibitor -
HY-W116606
Coumarin boronic acidFluorescence Probe -
HY-100113
BuloxibutidAT2R Agonist -
HY-120801A
APX-115 free basePan-Nox Inhibitor -
HY-N0637
EriodictyolEndogenous Metabolite -
HY-12298R
Setanaxib (Standard)NOX1/4 Inhibitor -
HY-113269
alpha-CEHCwater Soluble Metabolites
Product Information
Information
Aplicación
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
No. CAS 955272-06-7
-
Peso molecular 366.80
-
Fòrmula C19H15ClN4O2
-
SMILES
O=C1N(C2=CC=CC=C2Cl)NC(C1=C(C)N3CC4=NC=CC=C4)=CC3=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Laleu B, et, al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010 Nov 11;53(21):7715-30. [Content Brief]
[2]. Teixeira G, et, al. Therapeutic potential of NADPH oxidase 1/4 inhibitors. Br J Pharmacol. 2017 Jun;174(12):1647-1669. [Content Brief]
[3]. Schildknecht S, et, al. The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem. 2014;21(3):365-76. [Content Brief]
[4]. Sedeek M, et, al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010 Dec;299(6):F1348-58. [Content Brief]
[5]. Hwang JS, et, al. GKT136901 protects primary human brain microvascular endothelial cells against methamphetamine-induced blood-brain barrier dysfunction. Life Sci. 2020 Sep 1;256:117917. [Content Brief]
[6]. Sedeek M, et, al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond). 2013 Feb;124(3):191-202. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GKT136901 (Standard) Related Classifications
HY-101499R Related Classifications
Powered by Bioz